Impact of primary tumor resection in the management of metastatic well‐differentiated neuroendocrine tumors of the small bowel and pancreas

Abstract

AbstractPatients with gastroenteropancreatic (GEP) neuroendocrine tumors (NET) often present with advanced disease. Primary tumor resection (PTR) in the setting of unresectable metastatic disease is controversial. Most studies evaluating the impact of PTR on overall survival (OS) have been performed using large population‐based databases, with limited treatment related data. This study aims to determine whether PTR improves OS and progression‐free survival (PFS) in patients with metastatic well‐differentiated GEP‐NET. This is a retrospective single‐institution study of patients with metastatic well‐differentiated GEP‐NET between 1978 and 2021. The primary outcome was OS. The secondary outcome was PFS. Chi‐squared tests and Cox regression were used to perform univariate and multivariate analyses (MVA). OS and PFS were estimated using the Kaplan–Meier method and log‐rank test. Between 1978 and 2021, 505 patients presented with metastatic NET, 151 of whom had well‐differentiated GEP‐NET. PTR was performed in 31 PNET and 77 SBNET patients. PTR was associated with improved median OS for PNET (136 vs. 61 months, p = .003) and SBNET (not reached vs. 79 months, p<.001). On MVA, only higher grade (HR 3.70, 95%CI 1.49–9.17) and PTR (HR 0.21, 95%CI 0.08–0.53) influenced OS. PTR resulted in longer median PFS for patients with SBNET (46 vs. 28 months, p = .03) and a trend toward longer median PFS for patients with PNET (20 vs. 13 months, p = .07). In patients with metastatic well‐differentiated GEP‐NET, PTR is associated with improved OS and may be associated with improved PFS and should be considered in a multidisciplinary setting. Future prospective studies are needed to validate these findings.